首页/数据集/Mechanisms of EGFR-TKI (tyrosine kinase inhibitor) resistance

Mechanisms of EGFR-TKI (tyrosine kinase inhibitor) resistance

NIAID Data Ecosystem2026-03-12 收录

EGFR-TKI耐药性

非小细胞肺癌治疗

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA730670 数据链接链接失效反馈

官方服务：

资源简介：

Identification of the mechanism of resistance to EGFR-TKI and the target proteins for overcoming the resistance in EGFR Mutant Non-Small-Cell Lung Cancer

应用场景：

创建时间：

2021-05-18

网络药理学

非小细胞肺癌治疗

Network pharmacology analysis data, including analysis process and results.

科学数据银行2022-06-21 更新40

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

非小细胞肺癌治疗

MET抑制剂

aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of AL

Taylor & Francis Group2021-05-07 更新40

Dataset from Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.

非小细胞肺癌治疗

EGFR-TKI耐药性

The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dos

NIAID Data Ecosystem30

Studies included in the meta-analysis.

非小细胞肺癌治疗

手术评估

Abbreviations: MLND, mediastinal lymph node dissection; MLNS, mediastinal lymph node sampling; NSCLC, non-small cell lung cancer; ND, not derived.Studies included in the meta-analysis.

Figshare2015-12-02 更新40

Baseline characteristics.

非小细胞肺癌治疗

放化疗疗效评估

Background Retrospective evidence indicated potential survival benefit of consolidative stereotactic radiotherapy (SRT) in patients with metastatic driver mutation-negative non-small cell lung cancer

NIAID Data Ecosystem30

Mechanisms of EGFR-TKI (tyrosine kinase inhibitor) resistance

资源简介：

相关数据集